Overview

Targeted Retreatment of COPD Exacerbations

Status:
Completed

Trial end date:
2019-01-22

Target enrollment:

Participant gender:

Summary

This study investigates the effects of targeted re-treatment of patients who do not recover from an exacerbation of COPD. Half of the patients will receive ciprofloxacin while the other half will receive a placebo.

Phase:

Phase 3

Details

Lead Sponsor:

Imperial College London

Treatments:

Ciprofloxacin